Low-affinity CAR T cells demonstrated robust anti-tumor efficacy both in vitro and in a xenograft mouse model, meanwhile sparing primary cell lines expressing physiological levels of HER2/neu [52]. This evidence concerns the gene ERBB2 and neoplasm.